International Stand Alone Meeting 2009 - Reducing Cardiovascular Risk

Friday 2nd October 2009

Day 1 - Optimizing Treatment to Reduce Cardiovascular Risk

Berlin, Germany

The following presentations made at the International Stand Alone Meeting 2009 are available as webcasts under the respective links:

Welcome and opening remarks

Thomas Unger, Germany

Setting the scene

Björn Dahlöf, Sweden

The new evidence on risk reduction in hypertensive patients: recent mega-trials in context

Michael Böhm, Germany

Blocking the RAS to reduce risk – which way is the best?

Thomas Unger, Germany

Risk reduction with telmisartan in hypertension and target organ damage: current evidence

Bernard Aubert, Taiwan

Strategies for managing global cardiovascular risk

Bryan Williams, UK

Panel discussion

All

Doing it better: sharing the learning from the workshops

Facilitator and faculty

Addressing cardiovascular risk: what is the role for ARBs?

Michael Weber, USA

Addressing cardiovascular risk: interactive case study

Gordon McInnes, UK

Treatment adherence: a problem for patients and physicians

Arya M Sharma, Canada

Treatment adherence: interactive case study

Sarah Jarvis, UK

Summary and close

Bryan Williams, UK

^* Telmisartan is currently only approved for the treatment of hypertension

These webcasts follow the presentations held on occasion of the International Stand Alone Meeting 2009 between 1st - 3rd October 2009. They are reproduced here for your personal information. Pursuant to our Terms of Use any sort of reproduction or downloading, in total or in part, is prohibited.